Development and characterization of a chick embryo model of glucose exposure for investigating cardiac development
Frontiers in Physiology · 18.11.2026 · 17
DOI: 10.3389/fphys.2026.1982571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Physiology, online erschienen am 18.11.2026. Verfasst von Marina Nimmo und 4 weiteren Autor:innen. Die Arbeit nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association, National Institutes of Health.
Abstract (Originalsprache)
Introduction
Congenital heart defects (CHDs) are the most common birth defect, and babies born to mothers with pregestational diabetes or prediabetes are three to five times more likely to develop CHDs. This increased risk is closely associated with periods of maternal hyperglycemia, during which excess glucose crosses the placenta and alters the embryonic environment during organogenesis. However, the consequences of mildly elevated glucose availability beginning in early development remain poorly understood, highlighting the need for physiologically relevant experimental models. In this study, we investigated the effects of increasing total available glucose on cardiac structure and function in an avian embryo model, with the goals of characterizing the model and identifying alterations in structure-function relationships in the developing heart.
Methods
Prior to incubation, Gallus gallus embryos were injected directly into the yolk with a 0.10 mL volume containing 50 or 100 mM D-glucose, with unopened, vehicle, and dose-equivalent L-glucose control groups included to distinguish metabolic glucose-specific effects from those associated with non-metabolic effects of excess available glucose or the injection procedure. Cardiac structure and function were assessed using micro-computed tomography and echocardiography on day 13 of development, when cardiac morphogenesis is largely complete.
Results
Increased yolk glucose availability was associated with structural remodeling and an increased overall CHD incidence (p < 0.001), including hypertrophic cardiomyopathy (HCM), double-outlet right ventricle (DORV), and isolated ventricular septal defect (VSD). CHDs were observed following both D- and L-glucose administration, indicating that non-metabolic factors may contribute to the observed structural abnormalities. Despite the presence of overt structural abnormalities, cardiac function was largely preserved. Whole blood glucose measured on day 13 was not significantly different among treatment groups, indicating that hyperglycemia was not detected at this developmental stage.
Discussion
Together, these findings demonstrate that increased glucose availability is associated with cardiac structural abnormalities without overt left ventricular dysfunction at day 13 of development in G. gallus embryos, and that non-metabolic effects of glucose may contribute. More broadly, this work supports the avian embryo as a model for investigating the metabolic and non-metabolic mechanisms contributing to glucose-associated cardiac malformations during embryonic development.
Förderung
- American Heart Association
- National Institutes of Health
Zitieren
APA
Nimmo, M., Mosquera-Lopez, C., Pedrizzetti, G., Maloyan, A., & Rugonyi, S. (2026). Development and characterization of a chick embryo model of glucose exposure for investigating cardiac development. Frontiers in Physiology, 17. https://doi.org/10.3389/fphys.2026.1982571
Vancouver
Nimmo M, Mosquera-Lopez C, Pedrizzetti G, Maloyan A, Rugonyi S. Development and characterization of a chick embryo model of glucose exposure for investigating cardiac development. Frontiers in Physiology. 2026;17. doi:10.3389/fphys.2026.1982571
BibTeX
@article{Nimmo2026,
author = {Nimmo, Marina and Mosquera-Lopez, Clara and Pedrizzetti, Gianni and Maloyan, Alina and Rugonyi, Sandra},
title = {Development and characterization of a chick embryo model of glucose exposure for investigating cardiac development},
journal = {Frontiers in Physiology},
year = {2026},
volume = {17},
doi = {10.3389/fphys.2026.1982571}
}
EUVIMED